GT Biopharma Inc
GTBP
Company Profile
Business description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Contact
315 Montgomery Street
10th Floor
San FranciscoCA94104
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
We believe Disney’s irreplaceable characters will continue to drive a healthy experiences business, which we estimate is worth nearly as much as the market values the whole firm.
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,706.15 | 6.44 | 0.07% |
| DAX 40 | 26,242.28 | 102.15 | 0.39% |
| Dow JONES (US) | 53,885.10 | 464.02 | -0.85% |
| FTSE 100 | 10,885.30 | 17.41 | 0.16% |
| HKSE | 25,646.33 | 116.05 | 0.45% |
| NASDAQ | 26,348.35 | 15.09 | -0.06% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,709.96 | 13.59 | -0.18% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |